Expressed Competent Cells Comprehensive Study by Type (Chemically Competent Cells, Electro-Competent Cells), Application (Plasmid DNA, Bacterial Transformation, Cloning), Method (Natural Competence, Artificial Competence), End User (Hospitals, Clinical Laboratories, Pharmaceuticals, Other) Players and Region - Global Market Outlook to 2027

Expressed Competent Cells Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Expressed Competent Cells
Expressed Competent Cells are the bacterial cells that can take up the foreign DNA from the surroundings by a process called transformation. This cells are made by heat shock treatment and calcium chloride. The cells growing rapidly can be made competent more easily than those in other stages of growth. After transformation, cells can express the acquired genetic information. This method is widely used to introduce recombinant plasmid DNA into competent bacterial cells. This process does not require donor cells, only DNA in the environment. Expressed Competent cells have altered cell walls that allow easy passage of DNA. Some cells need to undergo some chemical or electrical treatment to make them efficient. Calcium ion treatment is a standard procedure for these cell preparations. Bacterial cells can also take up DNA through a process called electroporation.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The market for Expressed Competent Cells is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as product innovation and using various marketing strategies to gain a higher market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Expressed Competent Cells market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Group (Germany), Sigma Aldrich (United States), Thermo Fisher Scientific (United States), Agilent (United States), Takara Bio (Japan), GoldBio (United States), Promega Corporation (United States), Bio Rad Laboratories (United States), Illumina Inc (United States) and Quiagen NV (Netherlands) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Meridian Bioscience, Inc (United States).

Segmentation Overview
AMA Research has segmented the market of Global Expressed Competent Cells market by Type (Chemically Competent Cells and Electro-Competent Cells), Application (Plasmid DNA, Bacterial Transformation and Cloning) and Region.



On the basis of geography, the market of Expressed Competent Cells has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Method, the sub-segment i.e. Natural Competence will boost the Expressed Competent Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Expressed Competent Cells market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Uses of Artificial Intelligence in Expressed Competent Cells Processing

Market Growth Drivers:
Surge in Demand Molecular Cloning in Health Research and Rising Demand in Protein Expression in Healthcare

Challenges:
Lack of Skilled Professional for Expressed Competent Cells, Low Penetration in Developing Regions and Lack of Freezer Space for Expressed Competent Cells Storing

Restraints:
High Cost Capital Investment associated with Expressed Competent Cells

Opportunities:
Continuous Growth in Healthcare Sectors and Research and Development

On 2 April 2022 Thermo Fisher Scientificís new Gibco CTS Xenon Electroporation System aims to provide easier scale up for cell therapies, from clinical development to commercial manufacturing. Thermo Fisher Scientific introduced a new large-volume electroporation system on March 16, 2022 that is intended to enable the development of cell therapies. The systemís goal is to allow cell therapy developers to move more easily from clinical development to commercial manufacturing.
The Food and Drug Administrationís Center for Biologics Evaluation and Research is responsible for regulation of cellular and tissue-based therapies in the U.S. An overview of FDAís regulatory approach is described below. Based on a tiered, risk-based approach for the regulation of cellular and tissue-based therapies, the FDA has established two primary regulatory pathways for these products. Under the first scheme, cellular therapy products that meet all the criteria in 21 CFR 1271.10(a) are regulated solely as HCT/Ps and are not required to be licensed, approved or cleared.

Key Target Audience
Expressed Competent Cells Manufacturers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Chemically Competent Cells
  • Electro-Competent Cells
By Application
  • Plasmid DNA
  • Bacterial Transformation
  • Cloning
By Method
  • Natural Competence
  • Artificial Competence

By End User
  • Hospitals
  • Clinical Laboratories
  • Pharmaceuticals
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge in Demand Molecular Cloning in Health Research
      • 3.2.2. Rising Demand in Protein Expression in Healthcare
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professional for Expressed Competent Cells
      • 3.3.2. Low Penetration in Developing Regions
      • 3.3.3. Lack of Freezer Space for Expressed Competent Cells Storing
    • 3.4. Market Trends
      • 3.4.1. Uses of Artificial Intelligence in Expressed Competent Cells Processing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Expressed Competent Cells, by Type, Application, Method, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Expressed Competent Cells (Value)
      • 5.2.1. Global Expressed Competent Cells by: Type (Value)
        • 5.2.1.1. Chemically Competent Cells
        • 5.2.1.2. Electro-Competent Cells
      • 5.2.2. Global Expressed Competent Cells by: Application (Value)
        • 5.2.2.1. Plasmid DNA
        • 5.2.2.2. Bacterial Transformation
        • 5.2.2.3. Cloning
      • 5.2.3. Global Expressed Competent Cells by: Method (Value)
        • 5.2.3.1. Natural Competence
        • 5.2.3.2. Artificial Competence
      • 5.2.4. Global Expressed Competent Cells by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Clinical Laboratories
        • 5.2.4.3. Pharmaceuticals
        • 5.2.4.4. Other
      • 5.2.5. Global Expressed Competent Cells Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Expressed Competent Cells (Price)
      • 5.3.1. Global Expressed Competent Cells by: Type (Price)
  • 6. Expressed Competent Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Group (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sigma Aldrich (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Agilent (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Takara Bio (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GoldBio (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Promega Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bio Rad Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Illumina Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quiagen NV (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Expressed Competent Cells Sale, by Type, Application, Method, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Expressed Competent Cells (Value)
      • 7.2.1. Global Expressed Competent Cells by: Type (Value)
        • 7.2.1.1. Chemically Competent Cells
        • 7.2.1.2. Electro-Competent Cells
      • 7.2.2. Global Expressed Competent Cells by: Application (Value)
        • 7.2.2.1. Plasmid DNA
        • 7.2.2.2. Bacterial Transformation
        • 7.2.2.3. Cloning
      • 7.2.3. Global Expressed Competent Cells by: Method (Value)
        • 7.2.3.1. Natural Competence
        • 7.2.3.2. Artificial Competence
      • 7.2.4. Global Expressed Competent Cells by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Clinical Laboratories
        • 7.2.4.3. Pharmaceuticals
        • 7.2.4.4. Other
      • 7.2.5. Global Expressed Competent Cells Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Expressed Competent Cells (Price)
      • 7.3.1. Global Expressed Competent Cells by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Expressed Competent Cells: by Type(USD Million)
  • Table 2. Expressed Competent Cells Chemically Competent Cells , by Region USD Million (2016-2021)
  • Table 3. Expressed Competent Cells Electro-Competent Cells , by Region USD Million (2016-2021)
  • Table 4. Expressed Competent Cells: by Application(USD Million)
  • Table 5. Expressed Competent Cells Plasmid DNA , by Region USD Million (2016-2021)
  • Table 6. Expressed Competent Cells Bacterial Transformation , by Region USD Million (2016-2021)
  • Table 7. Expressed Competent Cells Cloning , by Region USD Million (2016-2021)
  • Table 8. Expressed Competent Cells: by Method(USD Million)
  • Table 9. Expressed Competent Cells Natural Competence , by Region USD Million (2016-2021)
  • Table 10. Expressed Competent Cells Artificial Competence , by Region USD Million (2016-2021)
  • Table 11. Expressed Competent Cells: by End User(USD Million)
  • Table 12. Expressed Competent Cells Hospitals , by Region USD Million (2016-2021)
  • Table 13. Expressed Competent Cells Clinical Laboratories , by Region USD Million (2016-2021)
  • Table 14. Expressed Competent Cells Pharmaceuticals , by Region USD Million (2016-2021)
  • Table 15. Expressed Competent Cells Other , by Region USD Million (2016-2021)
  • Table 16. South America Expressed Competent Cells, by Country USD Million (2016-2021)
  • Table 17. South America Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 18. South America Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 19. South America Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 20. South America Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 21. Brazil Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 22. Brazil Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 23. Brazil Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 24. Brazil Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 25. Argentina Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 26. Argentina Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 27. Argentina Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 28. Argentina Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 29. Rest of South America Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 30. Rest of South America Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 31. Rest of South America Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 32. Rest of South America Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 33. Asia Pacific Expressed Competent Cells, by Country USD Million (2016-2021)
  • Table 34. Asia Pacific Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 35. Asia Pacific Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 36. Asia Pacific Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 37. Asia Pacific Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 38. China Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 39. China Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 40. China Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 41. China Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 42. Japan Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 43. Japan Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 44. Japan Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 45. Japan Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 46. India Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 47. India Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 48. India Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 49. India Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 50. South Korea Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 51. South Korea Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 52. South Korea Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 53. South Korea Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 54. Australia Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 55. Australia Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 56. Australia Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 57. Australia Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 58. Rest of Asia-Pacific Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 59. Rest of Asia-Pacific Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 60. Rest of Asia-Pacific Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 62. Europe Expressed Competent Cells, by Country USD Million (2016-2021)
  • Table 63. Europe Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 64. Europe Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 65. Europe Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 66. Europe Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 67. Germany Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 68. Germany Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 69. Germany Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 70. Germany Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 71. France Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 72. France Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 73. France Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 74. France Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 75. Italy Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 76. Italy Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 77. Italy Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 78. Italy Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 79. United Kingdom Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 80. United Kingdom Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 81. United Kingdom Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 82. United Kingdom Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 83. Netherlands Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 84. Netherlands Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 85. Netherlands Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 86. Netherlands Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 87. Rest of Europe Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 88. Rest of Europe Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 89. Rest of Europe Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 90. Rest of Europe Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 91. MEA Expressed Competent Cells, by Country USD Million (2016-2021)
  • Table 92. MEA Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 93. MEA Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 94. MEA Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 95. MEA Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 96. Middle East Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 97. Middle East Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 98. Middle East Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 99. Middle East Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 100. Africa Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 101. Africa Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 102. Africa Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 103. Africa Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 104. North America Expressed Competent Cells, by Country USD Million (2016-2021)
  • Table 105. North America Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 106. North America Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 107. North America Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 108. North America Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 109. United States Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 110. United States Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 111. United States Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 112. United States Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 113. Canada Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 114. Canada Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 115. Canada Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 116. Canada Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 117. Mexico Expressed Competent Cells, by Type USD Million (2016-2021)
  • Table 118. Mexico Expressed Competent Cells, by Application USD Million (2016-2021)
  • Table 119. Mexico Expressed Competent Cells, by Method USD Million (2016-2021)
  • Table 120. Mexico Expressed Competent Cells, by End User USD Million (2016-2021)
  • Table 121. Expressed Competent Cells: by Type(USD/Units)
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Expressed Competent Cells: by Type(USD Million)
  • Table 133. Expressed Competent Cells Chemically Competent Cells , by Region USD Million (2022-2027)
  • Table 134. Expressed Competent Cells Electro-Competent Cells , by Region USD Million (2022-2027)
  • Table 135. Expressed Competent Cells: by Application(USD Million)
  • Table 136. Expressed Competent Cells Plasmid DNA , by Region USD Million (2022-2027)
  • Table 137. Expressed Competent Cells Bacterial Transformation , by Region USD Million (2022-2027)
  • Table 138. Expressed Competent Cells Cloning , by Region USD Million (2022-2027)
  • Table 139. Expressed Competent Cells: by Method(USD Million)
  • Table 140. Expressed Competent Cells Natural Competence , by Region USD Million (2022-2027)
  • Table 141. Expressed Competent Cells Artificial Competence , by Region USD Million (2022-2027)
  • Table 142. Expressed Competent Cells: by End User(USD Million)
  • Table 143. Expressed Competent Cells Hospitals , by Region USD Million (2022-2027)
  • Table 144. Expressed Competent Cells Clinical Laboratories , by Region USD Million (2022-2027)
  • Table 145. Expressed Competent Cells Pharmaceuticals , by Region USD Million (2022-2027)
  • Table 146. Expressed Competent Cells Other , by Region USD Million (2022-2027)
  • Table 147. South America Expressed Competent Cells, by Country USD Million (2022-2027)
  • Table 148. South America Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 149. South America Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 150. South America Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 151. South America Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 152. Brazil Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 153. Brazil Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 154. Brazil Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 155. Brazil Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 156. Argentina Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 157. Argentina Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 158. Argentina Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 159. Argentina Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 160. Rest of South America Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 161. Rest of South America Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 162. Rest of South America Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 163. Rest of South America Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 164. Asia Pacific Expressed Competent Cells, by Country USD Million (2022-2027)
  • Table 165. Asia Pacific Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 166. Asia Pacific Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 167. Asia Pacific Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 168. Asia Pacific Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 169. China Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 170. China Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 171. China Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 172. China Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 173. Japan Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 174. Japan Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 175. Japan Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 176. Japan Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 177. India Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 178. India Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 179. India Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 180. India Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 181. South Korea Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 182. South Korea Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 183. South Korea Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 184. South Korea Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 185. Australia Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 186. Australia Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 187. Australia Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 188. Australia Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 189. Rest of Asia-Pacific Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 190. Rest of Asia-Pacific Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 191. Rest of Asia-Pacific Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 192. Rest of Asia-Pacific Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 193. Europe Expressed Competent Cells, by Country USD Million (2022-2027)
  • Table 194. Europe Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 195. Europe Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 196. Europe Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 197. Europe Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 198. Germany Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 199. Germany Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 200. Germany Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 201. Germany Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 202. France Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 203. France Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 204. France Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 205. France Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 206. Italy Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 207. Italy Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 208. Italy Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 209. Italy Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 210. United Kingdom Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 211. United Kingdom Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 212. United Kingdom Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 213. United Kingdom Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 214. Netherlands Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 215. Netherlands Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 216. Netherlands Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 217. Netherlands Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 218. Rest of Europe Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 219. Rest of Europe Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 220. Rest of Europe Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 221. Rest of Europe Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 222. MEA Expressed Competent Cells, by Country USD Million (2022-2027)
  • Table 223. MEA Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 224. MEA Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 225. MEA Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 226. MEA Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 227. Middle East Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 228. Middle East Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 229. Middle East Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 230. Middle East Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 231. Africa Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 232. Africa Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 233. Africa Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 234. Africa Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 235. North America Expressed Competent Cells, by Country USD Million (2022-2027)
  • Table 236. North America Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 237. North America Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 238. North America Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 239. North America Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 240. United States Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 241. United States Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 242. United States Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 243. United States Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 244. Canada Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 245. Canada Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 246. Canada Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 247. Canada Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 248. Mexico Expressed Competent Cells, by Type USD Million (2022-2027)
  • Table 249. Mexico Expressed Competent Cells, by Application USD Million (2022-2027)
  • Table 250. Mexico Expressed Competent Cells, by Method USD Million (2022-2027)
  • Table 251. Mexico Expressed Competent Cells, by End User USD Million (2022-2027)
  • Table 252. Expressed Competent Cells: by Type(USD/Units)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Expressed Competent Cells: by Type USD Million (2016-2021)
  • Figure 5. Global Expressed Competent Cells: by Application USD Million (2016-2021)
  • Figure 6. Global Expressed Competent Cells: by Method USD Million (2016-2021)
  • Figure 7. Global Expressed Competent Cells: by End User USD Million (2016-2021)
  • Figure 8. South America Expressed Competent Cells Share (%), by Country
  • Figure 9. Asia Pacific Expressed Competent Cells Share (%), by Country
  • Figure 10. Europe Expressed Competent Cells Share (%), by Country
  • Figure 11. MEA Expressed Competent Cells Share (%), by Country
  • Figure 12. North America Expressed Competent Cells Share (%), by Country
  • Figure 13. Global Expressed Competent Cells: by Type USD/Units (2016-2021)
  • Figure 14. Global Expressed Competent Cells share by Players 2021 (%)
  • Figure 15. Global Expressed Competent Cells share by Players (Top 3) 2021(%)
  • Figure 16. Global Expressed Competent Cells share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck Group (Germany) Revenue: by Geography 2021
  • Figure 20. Sigma Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 21. Sigma Aldrich (United States) Revenue: by Geography 2021
  • Figure 22. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 23. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 24. Agilent (United States) Revenue, Net Income and Gross profit
  • Figure 25. Agilent (United States) Revenue: by Geography 2021
  • Figure 26. Takara Bio (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Takara Bio (Japan) Revenue: by Geography 2021
  • Figure 28. GoldBio (United States) Revenue, Net Income and Gross profit
  • Figure 29. GoldBio (United States) Revenue: by Geography 2021
  • Figure 30. Promega Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Promega Corporation (United States) Revenue: by Geography 2021
  • Figure 32. Bio Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 33. Bio Rad Laboratories (United States) Revenue: by Geography 2021
  • Figure 34. Illumina Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Illumina Inc (United States) Revenue: by Geography 2021
  • Figure 36. Quiagen NV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 37. Quiagen NV (Netherlands) Revenue: by Geography 2021
  • Figure 38. Global Expressed Competent Cells: by Type USD Million (2022-2027)
  • Figure 39. Global Expressed Competent Cells: by Application USD Million (2022-2027)
  • Figure 40. Global Expressed Competent Cells: by Method USD Million (2022-2027)
  • Figure 41. Global Expressed Competent Cells: by End User USD Million (2022-2027)
  • Figure 42. South America Expressed Competent Cells Share (%), by Country
  • Figure 43. Asia Pacific Expressed Competent Cells Share (%), by Country
  • Figure 44. Europe Expressed Competent Cells Share (%), by Country
  • Figure 45. MEA Expressed Competent Cells Share (%), by Country
  • Figure 46. North America Expressed Competent Cells Share (%), by Country
  • Figure 47. Global Expressed Competent Cells: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Merck Group (Germany)
  • Sigma Aldrich (United States)
  • Thermo Fisher Scientific (United States)
  • Agilent (United States)
  • Takara Bio (Japan)
  • GoldBio (United States)
  • Promega Corporation (United States)
  • Bio Rad Laboratories (United States)
  • Illumina Inc (United States)
  • Quiagen NV (Netherlands)
Additional players considered in the study are as follows:
Meridian Bioscience, Inc (United States)
Select User Access Type

Key Highlights of Report


Sep 2022 218 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Group (Germany), Sigma Aldrich (United States), Thermo Fisher Scientific (United States), Agilent (United States), Takara Bio (Japan), GoldBio (United States), Promega Corporation (United States), Bio Rad Laboratories (United States), Illumina Inc (United States) and Quiagen NV (Netherlands) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Uses of Artificial Intelligence in Expressed Competent Cells Processing" is seen as one of major influencing trends for Expressed Competent Cells Market during projected period 2021-2027.
The Expressed Competent Cells market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Expressed Competent Cells Market Report?